Impact Biomedical (IBO) Deferred Taxes (2022)
Impact Biomedical's (IBO) quarterly Deferred Taxes came in at -$1.9 million in Q4 2022.
Powered by 
Analysis
Impact Biomedical (IBO) Deferred Taxes (2022) Analysis & Trends
Impact Biomedical (IBO) has reported Deferred Taxes for 1 consecutive years, with -$1.9 million the latest figure, recorded in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -291.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -587.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -69.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 194.40 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -27.60 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 | - |